Indication and adverse event profiles of denosumab and zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS).

Front Pharmacol · 2023 · PMC10654638 · PMID 38027014

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The chart shows an increasing trend in AEs for both drugs year by year, but a decline in 2012 and 2018 for ZA and Dmab, respectively.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.